# Quanto Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quanto-bio

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.quantobio.com
- Total disclosed funding: $7.1M
- Latest round: Series C (Jun 4, 2015)
- Investors on record: 3

## About

Quanto Bio is a biotechnology company focused on developing innovative diagnostic solutions in oncology and infectious diseases. Their products aim to enhance healthcare by facilitating rapid and accurate medical testing.Founded in 2009 in Beijing, China, Quanto Bio specializes in diagnostic products. The company was established as a result of a merger and has consistently focused on expanding its product line. They received their latest funding in Series C round of CNY 20.000 mn in January 2016 from Shenzhen Yuankang Investment Management, raising a total of CNY 20.000 mn since inception.Quanto Bio specializes in a range of diagnostic products primarily focused on oncology and infectious diseases. Their offerings include flow diagnostic systems, tumor screening series, tuberculosis diagnostic products, and molecular diagnostic solutions, designed to provide accurate and rapid testing. The company serves hospitals, laboratories, and research institutions in domestic and select international markets, aiding in early detection and treatment through efficient diagnostic processes.In 2019, Quanto Bio generated revenue of CNY 15,353,056.30 with an EBITDA of -CNY 2,244,819.60. Their business model is primarily B2B, engaging healthcare institutions and laboratories that require their diagnostic products, often through bulk order contracts.Quanto Bio is focused on launching new diagnostic products aimed at improving patient outcomes, with plans to expand into international markets by 2025. The recent funding from their Series C round will support product development and market expansion initiatives, following their listing on the New Third Board (NEEQ) in January 2016.

## Funding rounds

- Series C, Jun 4, 2015, $3.3M — Zhenghe Island, Shenzhen Yuankang Investment Management
- Series B, Jul 29, 2014, $1.6M — Lotus Lake Capital
- Series A, Dec 31, 2013, $2.2M — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A, Series B
- Zhenghe Island (https://capitalatlas.ai/funds/zhenghe-island) — Series C
- Shenzhen Yuankang Investment Management — Series C